MYRIAD GENETICS INC (MYGN) Stock News
NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD
MYGN Latest News, Press Relases and Analysis
Top movers in Wednesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Wednesday's session: top gainers and losers
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Paul Singer’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other stock picks with huge upside potential. Paul Singer founded Elliott Investment Management in 1977 in New York. It is one of the […]
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround
Myriad (MYGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges.
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk...
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and EBITDA guidance due to weaker trends in its pharmacogenomics and hereditary cancer testing (women's health) businesses. On the other hand, MYGN significantly beat analysts' EPS and EBITDA expectations. Overall, this was a softer quarter.
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at the gap up and gap down stocks in today's session.
MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook
Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.
These stocks that are showing activity before the opening bell on Wednesday.
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 2.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: WVE
Which stocks are moving after the closing bell on Tuesday?
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5%...
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns...
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Management will participate in two upcoming investor healthcare conferences
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Management will participate in two upcoming investor healthcare conferences...
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD...
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
Mentions: HOLX
Is UnitedHealth Group (UNH) the Best Low Volatility Stock to Buy Now?
We recently published a list of 10 Best Low Volatility Stocks to Buy Now. In this article, we are going to take a look at where UnitedHealth Group Incorporated (NYSE:UNH) stands against other best low volatility stocks to buy now. The US stock market experienced a turbulent first quarter of 2025, marked by increased volatility […]